{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-028472","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.289780+00:00","generated_at":"2026-06-05T09:07:43.399139+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa Q4 ARCALYST rev $71.2M (+15% YoY); FY2024 guidance $360-380M","bullets":["ARCALYST net product revenue $71.2M Q4 2023, $233.2M full-year 2023; ~9% of target 14,000 patients active on therapy.","2024 ARCALYST revenue guidance $360-380M, ~59% YoY growth at midpoint.","Q4 net income $25.2M vs $4.5M YoY; cash $206.4M, no debt, funds operations into at least 2027.","Abiprubart Phase 2 Cohort 4 data and new development indication expected April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-028472","json":"https://secwatch.observer/filing/0001104659-24-028472.json","markdown":"https://secwatch.observer/filing/0001104659-24-028472.md","text":"https://secwatch.observer/filing/0001104659-24-028472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/0001104659-24-028472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/tm247423d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:07:43.399139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60610364d17d15b2d9c30c75a0fc6cfa44512a24","claim":"Kiniksa Pharmaceuticals International, plc reported fourth quarter and full-year 2023 results: revenue $71.2 million and $233.2 million.","evidence_excerpt":"ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/0001104659-24-028472-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year 2023"},{"label":"Revenue","value":"$71.2 million and $233.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6dc0d2f27e1b2569b891b4c26d27f46ba3a1e75c","claim":"Kiniksa Pharmaceuticals International, plc reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On February 28, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/0001104659-24-028472-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}